Corvus Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8‑K on August 6, 2026 disclosing that it issued a press release reporting its financial results for the three and six months ended June 30, 2026 and providing a business update. The press release is furnished as Exhibit 99.1 to the filing. The report was signed by Leiv Lea, Chief Financial Officer.

Key Details

• Filing date: August 6, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Reporting periods covered: three and six months ended June 30, 2026.
• Press release containing the financial results and business update is Exhibit 99.1 to the Form 8-K.
• Form 8-K was executed by CFO Leiv Lea.

Why It Matters
This 8‑K signals that Corvus has publicly released its quarterly earnings and a business update—information investors use to assess quarterly results (revenue, expenses, net loss/profit) and the company’s financial position or operational progress. Retail investors should read the attached press release (Exhibit 99.1) for the specific financial metrics, any guidance or milestones mentioned, and to evaluate near‑term implications for the stock.